Cargando…

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain

Influenza infections impose a high burden of morbidity and mortality among older adults, at great cost to individuals and society. Enhanced influenza vaccines, which contain either an immune adjuvant or higher than normal doses of influenza virus antigens, are recommended for older adults. We used a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Aragón, Jesús, Márquez-Peláez, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967209/
https://www.ncbi.nlm.nih.gov/pubmed/36851304
http://dx.doi.org/10.3390/vaccines11020427
_version_ 1784897207664640000
author Ruiz-Aragón, Jesús
Márquez-Peláez, Sergio
author_facet Ruiz-Aragón, Jesús
Márquez-Peláez, Sergio
author_sort Ruiz-Aragón, Jesús
collection PubMed
description Influenza infections impose a high burden of morbidity and mortality among older adults, at great cost to individuals and society. Enhanced influenza vaccines, which contain either an immune adjuvant or higher than normal doses of influenza virus antigens, are recommended for older adults. We used a health economics model to evaluate the cost effectiveness in Spain of a recently licensed recombinant quadrivalent influenza vaccine (QIVr), which contains three times the standard dose of influenza virus hemagglutinin but no neuraminidase, compared with an MF59-adjuvanted quadrivalent influenza vaccine (aQIV). Based on current tender prices in Spain and a conservative assumption that QIVr is 10.7% relatively more effective than aQIV, the incremental cost-effectiveness ratio (ICER) for QIVr was EUR 101,612.41 per quality-adjusted life year (QALY) gained. To meet the Spanish willingness-to-pay threshold of EUR 25,000 per QALY gained, QIVr would need to be 34.1% relatively more effective than aQIV. In a probabilistic sensitivity analysis conducted to confirm the robustness of the analysis, 99.7% of simulations for QIVr were higher than the willingness-to-pay curve. These findings suggest that QIVr is not currently a cost-effective influenza vaccine option relative to aQIV for older persons living in Spain.
format Online
Article
Text
id pubmed-9967209
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99672092023-02-26 An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain Ruiz-Aragón, Jesús Márquez-Peláez, Sergio Vaccines (Basel) Article Influenza infections impose a high burden of morbidity and mortality among older adults, at great cost to individuals and society. Enhanced influenza vaccines, which contain either an immune adjuvant or higher than normal doses of influenza virus antigens, are recommended for older adults. We used a health economics model to evaluate the cost effectiveness in Spain of a recently licensed recombinant quadrivalent influenza vaccine (QIVr), which contains three times the standard dose of influenza virus hemagglutinin but no neuraminidase, compared with an MF59-adjuvanted quadrivalent influenza vaccine (aQIV). Based on current tender prices in Spain and a conservative assumption that QIVr is 10.7% relatively more effective than aQIV, the incremental cost-effectiveness ratio (ICER) for QIVr was EUR 101,612.41 per quality-adjusted life year (QALY) gained. To meet the Spanish willingness-to-pay threshold of EUR 25,000 per QALY gained, QIVr would need to be 34.1% relatively more effective than aQIV. In a probabilistic sensitivity analysis conducted to confirm the robustness of the analysis, 99.7% of simulations for QIVr were higher than the willingness-to-pay curve. These findings suggest that QIVr is not currently a cost-effective influenza vaccine option relative to aQIV for older persons living in Spain. MDPI 2023-02-13 /pmc/articles/PMC9967209/ /pubmed/36851304 http://dx.doi.org/10.3390/vaccines11020427 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ruiz-Aragón, Jesús
Márquez-Peláez, Sergio
An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
title An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
title_full An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
title_fullStr An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
title_full_unstemmed An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
title_short An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
title_sort economic comparison in the elderly of adjuvanted quadrivalent influenza vaccine with recombinant quadrivalent influenza vaccine in spain
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967209/
https://www.ncbi.nlm.nih.gov/pubmed/36851304
http://dx.doi.org/10.3390/vaccines11020427
work_keys_str_mv AT ruizaragonjesus aneconomiccomparisonintheelderlyofadjuvantedquadrivalentinfluenzavaccinewithrecombinantquadrivalentinfluenzavaccineinspain
AT marquezpelaezsergio aneconomiccomparisonintheelderlyofadjuvantedquadrivalentinfluenzavaccinewithrecombinantquadrivalentinfluenzavaccineinspain
AT ruizaragonjesus economiccomparisonintheelderlyofadjuvantedquadrivalentinfluenzavaccinewithrecombinantquadrivalentinfluenzavaccineinspain
AT marquezpelaezsergio economiccomparisonintheelderlyofadjuvantedquadrivalentinfluenzavaccinewithrecombinantquadrivalentinfluenzavaccineinspain